159 related articles for article (PubMed ID: 10964329)
21. Cathepsins B and L in synovial fluids from patients with rheumatoid arthritis and the effect of cathepsin B on the activation of pro-urokinase.
Ikeda Y; Ikata T; Mishiro T; Nakano S; Ikebe M; Yasuoka S
J Med Invest; 2000 Feb; 47(1-2):61-75. PubMed ID: 10740981
[TBL] [Abstract][Full Text] [Related]
22. Cathepsin B, a prognostic indicator in lymph node-negative breast carcinoma patients: comparison with cathepsin D, cathepsin L, and other clinical indicators.
Lah TT; Cercek M; Blejec A; Kos J; Gorodetsky E; Somers R; Daskal I
Clin Cancer Res; 2000 Feb; 6(2):578-84. PubMed ID: 10690542
[TBL] [Abstract][Full Text] [Related]
23. Expression of plasminogen activators and plasminogen activator inhibitor 1 in dedifferentiated chondrosarcoma.
Häckel C; Czerniak B; Ayala AG; Radig K; Roessner A
Cancer; 1997 Jan; 79(1):53-8. PubMed ID: 8988726
[TBL] [Abstract][Full Text] [Related]
24. Overexpression level of stromelysin 3 is related to the lymph node involvement in non-small cell lung cancer.
Delebecq TJ; Porte H; Zerimech F; Copin MC; Gouyer V; Dacquembronne E; Balduyck M; Wurtz A; Huet G
Clin Cancer Res; 2000 Mar; 6(3):1086-92. PubMed ID: 10741738
[TBL] [Abstract][Full Text] [Related]
25. Variable expression of cathepsin B and D correlates with highly invasive and metastatic phenotype of oral cancer.
Vigneswaran N; Zhao W; Dassanayake A; Muller S; Miller DM; Zacharias W
Hum Pathol; 2000 Aug; 31(8):931-7. PubMed ID: 10987253
[TBL] [Abstract][Full Text] [Related]
26. Role of urokinase plasminogen activator and its receptor in metastasis and invasion of neuroblastoma.
Li P; Gao Y; Ji Z; Zhang X; Xu Q; Li G; Guo Z; Zheng B; Guo X
J Pediatr Surg; 2004 Oct; 39(10):1512-9. PubMed ID: 15486896
[TBL] [Abstract][Full Text] [Related]
27. Clinical value of extended biologic staging by bone marrow micrometastases and tumor-associated proteases in gastric cancer.
Heiss MM; Allgayer H; Gruetzner KU; Babic R; Jauch KW; Schildberg FW
Ann Surg; 1997 Dec; 226(6):736-44; discussion 744-5. PubMed ID: 9409572
[TBL] [Abstract][Full Text] [Related]
28. Simultaneous expression of Cathepsins B and K in pulmonary adenocarcinomas and squamous cell carcinomas predicts poor recurrence-free and overall survival.
Cordes C; Bartling B; Simm A; Afar D; Lautenschläger C; Hansen G; Silber RE; Burdach S; Hofmann HS
Lung Cancer; 2009 Apr; 64(1):79-85. PubMed ID: 18760860
[TBL] [Abstract][Full Text] [Related]
29. Nitric oxide synthases, cyclooxygenase-2, nitrotyrosine, and angiogenesis in chondrosarcoma and their relation to prognosis.
Nakagawa SA; Lopes A; Lopes de Carvalho A; Rossi BM; Werneck da Cunha I; Soares FA; Chung WT; Alves LA
J Bone Joint Surg Am; 2010 Jul; 92(8):1738-46. PubMed ID: 20660237
[TBL] [Abstract][Full Text] [Related]
30. Immunostained cathepsins B and L correlate with depth of invasion and different metastatic pathways in early stage gastric carcinoma.
Dohchin A; Suzuki JI; Seki H; Masutani M; Shiroto H; Kawakami Y
Cancer; 2000 Aug; 89(3):482-7. PubMed ID: 10931446
[TBL] [Abstract][Full Text] [Related]
31. Association between ratio of matrix metalloproteinase-1 to tissue inhibitor of metalloproteinase-1 and local recurrence, metastasis, and survival in human chondrosarcoma.
Berend KR; Toth AP; Harrelson JM; Layfield LJ; Hey LA; Scully SP
J Bone Joint Surg Am; 1998 Jan; 80(1):11-7. PubMed ID: 9469303
[TBL] [Abstract][Full Text] [Related]
32. Expression of matrix metalloproteinases-1, -2, and -9; tissue inhibitors of matrix metalloproteinases-1 and -2; cathepsin B; urokinase plasminogen activator; and plasminogen activator inhibitor, type I in skull base chordoma.
Naka T; Kuester D; Boltze C; Schulz TO; Samii A; Herold C; Ostertag H; Roessner A
Hum Pathol; 2008 Feb; 39(2):217-23. PubMed ID: 17949787
[TBL] [Abstract][Full Text] [Related]
33. Complex of urokinase-type plasminogen activator with its type 1 inhibitor predicts poor outcome in 576 patients with lymph node-negative breast carcinoma.
Manders P; Tjan-Heijnen VC; Span PN; Grebenchtchikov N; Geurts-Moespot A; van Tienoven DT; Beex LV; Sweep FC
Cancer; 2004 Aug; 101(3):486-94. PubMed ID: 15274061
[TBL] [Abstract][Full Text] [Related]
34. Tumor-associated proteases and inhibitors in gastric cancer: analysis of prognostic impact and individual risk protease patterns.
Allgayer H; Babic R; Grützner KU; Beyer BC; Tarabichi A; Schildberg FW; Heiss MM
Clin Exp Metastasis; 1998 Jan; 16(1):62-73. PubMed ID: 9502078
[TBL] [Abstract][Full Text] [Related]
35. Expression of cathepsin L in nasopharyngeal carcinoma and its clinical significance.
Xu X; Yuan G; Liu W; Zhang Y; Chen W
Exp Oncol; 2009 Jun; 31(2):102-5. PubMed ID: 19550400
[TBL] [Abstract][Full Text] [Related]
36. Chondrosarcoma of the phalanx: a locally aggressive lesion with minimal metastatic potential: a report of 35 cases and a review of the literature.
Bovée JV; van der Heul RO; Taminiau AH; Hogendoorn PC
Cancer; 1999 Nov; 86(9):1724-32. PubMed ID: 10547545
[TBL] [Abstract][Full Text] [Related]
37. Expression of cathepsin D, stromelysin-3, and urokinase by reactive stromal cells on breast carcinoma prognosis.
Têtu B; Brisson J; Wang CS; Lapointe H; Beaudry G; Blanchette C
Cancer; 2001 Dec; 92(11):2957-64. PubMed ID: 11753972
[TBL] [Abstract][Full Text] [Related]
38. [The role of cathepsins and the plasminogen activator/inhibitor system in colorectal cancer].
Herszényi L; Farinati F; Plebani M; István G; Sápi Z; Carraro P; De Paoli M; Naccarato R; Tulassay Z
Orv Hetil; 1999 Aug; 140(33):1833-6. PubMed ID: 10489782
[TBL] [Abstract][Full Text] [Related]
39. An immunohistochemical assessment of cathepsin D in gastric carcinoma: its impact on clinical prognosis.
Allgayer H; Babic R; Grützner KU; Beyer BC; Tarabichi A; Wilhelm Schildberg F; Heiss MM
Cancer; 1997 Jul; 80(2):179-87. PubMed ID: 9217027
[TBL] [Abstract][Full Text] [Related]
40. [Protease activities in gastric and colon cancer tissues].
Chung SM; Kawai K; Chung HM; Kawamoto K; Tada M
Nihon Shokakibyo Gakkai Zasshi; 1990 Aug; 87(8):1678-85. PubMed ID: 2232301
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
